6/25
03:15 pm
rlmd
The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Securities Law Violations And Encourages Investors With Losses To Contact
Neutral
Report
The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Securities Law Violations And Encourages Investors With Losses To Contact
6/24
04:45 pm
rlmd
The Schall Law Firm Is Probing Relmada Therapeutics Inc For Possible Securities Law Breaches And Urges Investors Who Incurred Losses To Reach Out
Low
Report
The Schall Law Firm Is Probing Relmada Therapeutics Inc For Possible Securities Law Breaches And Urges Investors Who Incurred Losses To Reach Out
6/23
11:00 am
rlmd
Potential Violations Of Securities Laws By Relmada Therapeutics Inc Are Being Investigated By The Schall Law Firm Investors Who Have Suffered Losses Are Encouraged To Connect With The Firm
Low
Report
Potential Violations Of Securities Laws By Relmada Therapeutics Inc Are Being Investigated By The Schall Law Firm Investors Who Have Suffered Losses Are Encouraged To Connect With The Firm
6/22
11:00 am
rlmd
Possible Breaches Of Securities Laws By Relmada Therapeutics Inc Are Being Probed By The Schall Law Firm Investors With Financial Losses Are Invited To Reach Out To The Firm
Low
Report
Possible Breaches Of Securities Laws By Relmada Therapeutics Inc Are Being Probed By The Schall Law Firm Investors With Financial Losses Are Invited To Reach Out To The Firm
6/21
05:15 pm
rlmd
Potential Violations Of Securities Laws By Relmada Therapeutics Inc Are Being Investigated By The Schall Law Firm Investors Who Have Suffered Losses Are Encouraged To Connect With The Firm
Low
Report
Potential Violations Of Securities Laws By Relmada Therapeutics Inc Are Being Investigated By The Schall Law Firm Investors Who Have Suffered Losses Are Encouraged To Connect With The Firm
6/20
04:05 pm
rlmd
Possible Breaches Of Securities Laws By Relmada Therapeutics Inc Are Being Probed By The Schall Law Firm Investors With Financial Losses Are Invited To Reach Out To The Firm
Low
Report
Possible Breaches Of Securities Laws By Relmada Therapeutics Inc Are Being Probed By The Schall Law Firm Investors With Financial Losses Are Invited To Reach Out To The Firm
6/19
04:05 pm
rlmd
Potential Violations Of Securities Laws By Relmada Therapeutics Inc Are Under Investigation By The Schall Law Firm Investors Who Have Incurred Financial Losses Are Encouraged To Contact The Firm
Low
Report
Potential Violations Of Securities Laws By Relmada Therapeutics Inc Are Under Investigation By The Schall Law Firm Investors Who Have Incurred Financial Losses Are Encouraged To Contact The Firm
6/18
04:30 pm
rlmd
The Schall Law Firm Is Probing Potential Securities Breaches By Relmada Therapeutics Inc Investors With Monetary Losses Are Urged To Reach Out To The Firm
Low
Report
The Schall Law Firm Is Probing Potential Securities Breaches By Relmada Therapeutics Inc Investors With Monetary Losses Are Urged To Reach Out To The Firm
6/18
08:41 am
rlmd
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry [Yahoo! Finance]
Medium
Report
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry [Yahoo! Finance]
6/18
08:30 am
rlmd
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
Low
Report
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
6/17
07:15 pm
rlmd
Relmada Therapeutics Inc. (NASDAQ: RLMD) Under Investigation By Schall Law Firm For Potential Securities Violations. Investors Who Lost Money Encouraged To Contact The Firm
Low
Report
Relmada Therapeutics Inc. (NASDAQ: RLMD) Under Investigation By Schall Law Firm For Potential Securities Violations. Investors Who Lost Money Encouraged To Contact The Firm
6/11
07:45 pm
rlmd
Allegations Leveled At Cloudflare, Inc. (NYSE:NET): Schall Law Firm Begins Investigation And Calls On Impacted Investors To Reach Out
Low
Report
Allegations Leveled At Cloudflare, Inc. (NYSE:NET): Schall Law Firm Begins Investigation And Calls On Impacted Investors To Reach Out
6/11
07:45 pm
rlmd
Claims Against Relmada Therapeutics, Inc.: Schall Law Firm Starts Investigation And Invites Affected Investors To Get In Touch
Low
Report
Claims Against Relmada Therapeutics, Inc.: Schall Law Firm Starts Investigation And Invites Affected Investors To Get In Touch
6/10
07:30 am
rlmd
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
High
Report
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
6/9
11:00 am
rlmd
Accusations Made Against Relmada Therapeutics, Inc.: Schall Law Firm Commences Probe And Calls On Impacted Investors To Participate
High
Report
Accusations Made Against Relmada Therapeutics, Inc.: Schall Law Firm Commences Probe And Calls On Impacted Investors To Participate
6/8
11:00 am
rlmd
Charges Leveled At Relmada Therapeutics, Inc.: Schall Law Firm Begins Investigation And Invites Impacted Investors To Engage.
High
Report
Charges Leveled At Relmada Therapeutics, Inc.: Schall Law Firm Begins Investigation And Invites Impacted Investors To Engage.
6/7
07:00 pm
rlmd
Accusations Against Relmada Therapeutics, Inc.: Schall Law Firm Initiates Probe And Calls On Impacted Investors To Connect
Medium
Report
Accusations Against Relmada Therapeutics, Inc.: Schall Law Firm Initiates Probe And Calls On Impacted Investors To Connect
6/6
01:15 pm
rlmd
Allegations Against Relmada Therapeutics, Inc.: Schall Law Firm Starts Investigation and Urges Impacted Investors to Reach Out
Low
Report
Allegations Against Relmada Therapeutics, Inc.: Schall Law Firm Starts Investigation and Urges Impacted Investors to Reach Out
6/5
01:45 pm
rlmd
Relmada Therapeutics, Inc. Allegations: Schall Law Firm Initiates Inquiry and Invites Affected Investors to Connect
Low
Report
Relmada Therapeutics, Inc. Allegations: Schall Law Firm Initiates Inquiry and Invites Affected Investors to Connect
6/5
07:23 am
rlmd
Relmada Therapeutics, Inc. (NASDAQ: RLMD) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "sell" rating. They now have a $2.00 price target on the stock, down previously from $3.00.
Medium
Report
Relmada Therapeutics, Inc. (NASDAQ: RLMD) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "sell" rating. They now have a $2.00 price target on the stock, down previously from $3.00.
6/4
03:30 pm
rlmd
The Schall Law Firm is Initiating an Inquiry into Allegations Against Relmada Therapeutics, Inc. and is Inviting Investors who Have Incurred Losses to Reach Out
Low
Report
The Schall Law Firm is Initiating an Inquiry into Allegations Against Relmada Therapeutics, Inc. and is Inviting Investors who Have Incurred Losses to Reach Out
6/3
06:00 pm
rlmd
RLMD CRUCIAL INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
Medium
Report
RLMD CRUCIAL INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
6/3
07:38 am
rlmd
Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference [Yahoo! Finance]
Medium
Report
Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference [Yahoo! Finance]
6/3
07:30 am
rlmd
Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference
Medium
Report
Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference
6/2
11:00 am
rlmd
INVESTIGATION PROGRESS REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
Medium
Report
INVESTIGATION PROGRESS REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm